trichostatin A

Trichostatin is a lipid of Polyketides (PK) class. Trichostatin is associated with abnormalities such as Dentatorubral-Pallidoluysian Atrophy, PARAGANGLIOMAS 3, abnormal fragmented structure, Disintegration (morphologic abnormality) and Hyperostosis, Diffuse Idiopathic Skeletal. The involved functions are known as Acetylation, Cell Differentiation process, histone modification, Gene Silencing and Transcriptional Activation. Trichostatin often locates in CD41a, Hematopoietic System, Chromatin Structure, Blood and Endothelium. The associated genes with Trichostatin are SPI1 gene, CELL Gene, Chromatin, CXCR4 gene and DNMT1 gene. The related lipids are Butyrates, Promega, butyrate, Lipopolysaccharides and Steroids. The related experimental models are Knock-out, Mouse Model, Xenograft Model and Cancer Model.

Cross Reference

Introduction

To understand associated biological information of trichostatin A, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with trichostatin A?

trichostatin A is suspected in Infection, Morphologically altered structure, Ureteral obstruction, Photosensitization, Atherosclerosis, Hypertrophic Cardiomyopathy and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with trichostatin A

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adenocarcinoma, Papillary D000231 2 associated lipids
Adrenoleukodystrophy D000326 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Asthma D001249 52 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 139

PubChem Associated disorders and diseases

What pathways are associated with trichostatin A

Lipid pathways are not clear in current pathway databases. We organized associated pathways with trichostatin A through full-text articles, including metabolic pathways or pathways of biological mechanisms.

Related references are published most in these journals:

Pathway name Related literatures
Loading... please refresh the page if content is not showing up.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with trichostatin A?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with trichostatin A?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with trichostatin A?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with trichostatin A?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with trichostatin A?

Mouse Model

Mouse Model are used in the study 'Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer.' (Majid S et al., 2010), Mouse Model are used in the study 'Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy.' (Fang MZ et al., 2005) and Mouse Model are used in the study 'Histone deacetylase 3 mediates allergic skin inflammation by regulating expression of MCP1 protein.' (Kim Y et al., 2012).

Xenograft Model

Xenograft Model are used in the study 'Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.' (Landreville S et al., 2012), Xenograft Model are used in the study 'Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells.' (Moiseeva EP et al., 2007) and Xenograft Model are used in the study 'Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.' (Touma SE et al., 2005).

Cancer Model

Cancer Model are used in the study 'Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice.' (Sanderson L et al., 2004).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with trichostatin A

Download all related citations
Per page 10 20 50 100 | Total 3126
Authors Title Published Journal PubMed Link
Saha A et al. Synthesis and biological evaluation of a targeted DNA-binding transcriptional activator with HDAC8 inhibitory activity. 2013 Bioorg. Med. Chem. pmid:23719282
Schäfer S et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). 2008 Bioorg. Med. Chem. pmid:18054239
Whitehead L et al. Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. 2011 Bioorg. Med. Chem. pmid:21723733
Feng T et al. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). 2013 Bioorg. Med. Chem. pmid:23820574
Mukherjee P et al. Structural insights into the Plasmodium falciparum histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. 2008 Bioorg. Med. Chem. pmid:18362073
Di Micco S et al. Structural basis for the design and synthesis of selective HDAC inhibitors. 2013 Bioorg. Med. Chem. pmid:23693069
Shivashimpi GM et al. Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. 2007 Bioorg. Med. Chem. pmid:17881232
Giannini G et al. N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. 2009 Bioorg. Med. Chem. Lett. pmid:19285395
Lee S et al. Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. 2007 Bioorg. Med. Chem. Lett. pmid:17588744
Nishino N et al. Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. 2004 Bioorg. Med. Chem. Lett. pmid:15109626
Wang DF et al. QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids. 2004 Bioorg. Med. Chem. Lett. pmid:14741273
Desai D et al. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. 2010 Bioorg. Med. Chem. Lett. pmid:20167479
Jose B et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. 2004 Bioorg. Med. Chem. Lett. pmid:15454224
Pabba C et al. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. 2011 Bioorg. Med. Chem. Lett. pmid:21109435
Gupta PK et al. Inhibitors selective for HDAC6 in enzymes and cells. 2010 Bioorg. Med. Chem. Lett. pmid:20947351
Shinji C et al. Design and synthesis of phthalimide-type histone deacetylase inhibitors. 2005 Bioorg. Med. Chem. Lett. pmid:16137884
Vasudevan A et al. Heterocyclic ketones as inhibitors of histone deacetylase. 2003 Bioorg. Med. Chem. Lett. pmid:14592473
Choi E et al. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors. 2011 Bioorg. Med. Chem. Lett. pmid:21256006
Charrier C et al. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. 2007 Bioorg. Med. Chem. Lett. pmid:17897824
Van Ommeslaeghe K et al. Amide analogues of TSA: synthesis, binding mode analysis and HDAC inhibition. 2003 Bioorg. Med. Chem. Lett. pmid:12749885